百令胶囊联合羧甲司坦治疗AECOPD的疗效及对EOS、PCT、肺功能及应激反应指标的影响#br#

摘要/Abstract

摘要： 目的：探讨百令胶囊联合羧甲司坦治疗急性加重期慢性阻塞性肺疾病（AECOPD）的疗效及对嗜酸性粒细胞（EOS）、降钙素原（PCT）、肺功能及应激反应的影响。方法：以我院2021年3月至2023年3月收治的痰湿阻肺兼肺肾气虚证AECOPD患者112例为研究对象，按随机数字表法分为对照组及观察组，每组各56例。对照组在常规治疗基础上，予以口服羧甲司坦片；观察组在对照组治疗基础上，联合百令胶囊治疗。两组患者均治疗1周。比较两组患者的中医证候积分、肺功能、炎症因子、应激反应、免疫功能相关指标水平及不良反应发生率。结果：与治疗前相比，治疗后两组患者咳嗽气喘、痰多白粘、胃脘痞满及舌淡苔白等证候积分均降低，且观察组以上证候积分均低于对照组（P<0.05）；两组患者第1秒用力呼气量（FEV1）、FEV1占预计值百分比（FEV1pred%）、用力呼气量（FVC）均有升高，且观察组以上指标均高于对照组（P<0.05）；两组患者EOS、PCT水平均下降，且观察组EOS、PCT水平均低于对照组（P<0.05）；两组患者丙二醛（MDA）水平均降低，超氧化物歧化酶（SOD）水平均上升，且观察组MAD水平低于对照组，SOD水平高于对照组（P<0.05）；两组患者CD4+、CD4+/CD8+水平均升高，CD8+水平则降低，且观察组CD4+、CD4+/CD8+水平高于对照组，CD8+水平低于对照组(P<0.05)；两组患者不良反应发生率比较，差异无统计学意义（P>0.05）。结论：应用百令胶囊联合羧甲司坦治疗AECOPD疗效确切，患者肺功能增强，炎症及应激反应有所减轻，免疫功能提高，且不良反应较少。

关键词: 慢性阻塞性肺病, 急性加重期, 百令胶囊, 羧甲司坦, 嗜酸性粒细胞, 降钙素原

Abstract: Objective： To investigate the efficacy of Bailing capsule combined with carbocisteine in the treatment of acute exacerbation chronic obstructive pulmonary disease (AECOPD) and its effects on eosinophils (EOS)， procalcitonin (PCT)， lung function and stress response. Methods： A total of 112 AECOPD patients with the syndrome of phlegm-dampness accumulated in the lung and the syndrome of lung-kidney Qi deficiency treated in our hospital from March 2021 to March 2023 were selected as the research objects， and were divided into the control group and the observation group according to random number table method， with 56 cases in each group. The control group was given carbocisteine tablets on the basis of conventional symptomatic treatment， and the observation group was treated with Bailing capsule on the basis of the treatment of the control group. Both groups were treated for 1 week. The TCM syndrome scores， lung function， inflammatory factors， stress response， immune function levels and the incidence of adverse reactions of the two groups of patients were compared. Results： The syndrome scores of cough and asthma， white sticky phlegm， distension in the stomach and white tongue coating of patients in both groups decreased after treatment， and the scores of the observation group were lower than those of the control group after treatment(P<0.05) . FEV1， FEV1 pred% and FVC of patients in both groups increased after the treatment， and the above indexes of the observation group was higher than those of the control group (P<0.05). The level of EOS and PCT of the two groups of patients decreased after the treatment， and the EOS and PCT levels of patients in the observation group was lower than those of the control group (P<0.05). The MDA level decreased and SOD level increased in both groups after the treatment， and the MAD level of patients in the observation group was lower than that of the control group， while the SOD level of patients in the observation group was higher than that of the control group (P<0.05). The levels of CD4+ and CD4+/CD8+ increased in both groups， while the level of CD8+ decreased in both groups， and the CD4+ and CD4+/CD8+ levels of patients in the observation group were higher than those of the control group， CD8+ level of patients in the observation group was lower than that of the control group (P<0.05). There was no statistical difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion： Bailing capsule combined with carbocisteine is effective in the treatment of AECOPD， which can improve the lung function， reduce inflammation and stress response， improve immune function of the patients， and with low incidence of adverse reactions .

Key words: Chronic obstructive pulmonary disease, Acute exacerbation stage, Bailing capsule, Carbocisteine, Eosinophils, Procalcitonin

中图分类号:

R563

陈娟, 关微, 徐蕊华. 百令胶囊联合羧甲司坦治疗AECOPD的疗效及对EOS、PCT、肺功能及应激反应指标的影响#br#[J]. 中国医药导刊, 2023, 25(10): 1045-1050.

CHEN Juan, GUAN Wei, XU Ruihua. Efficacy of Bailing Capsule Combined with Carbocisteine in the Treatment of AECOPD and Its Effects on EOS， PCT， Lung Function and Stress Response#br#[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2023, 25(10): 1045-1050.

参考文献

[1]Mirza S， Clay RD， Koslow MA， et al. COPD guidelines： A review of the 2018 GOLD report[J]. Mayo Clin Proc， 2018， 93(10)：1488-1502.
[2]Chen X， Zhou CW， Fu YY， et al. Global， regional， and national burden of chronic respiratory diseases and associated risk factors， 1990-2019： Results from the Global Burden of Disease Study 2019[J]. Front Med (Lausanne)， 2023， 10：1066804.
[3]Yin P， Wu J， Wang L， et al. The burden of COPD in China and its provinces： findings from the global burden of disease study 2019[J]. Front Public Health， 2022， 10：859499.
[4]Yao C， Liu X， Tang Z. Prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio for hospital mortality in patients with AECOPD[J]. Int J Chron Obstruct Pulmon Dis， 2017， 12：2285-2290.
[5]Vogelmeier CF， Criner GJ， Martinez FJ， et al. Global Strategy for the Diagnosis， Management， and Prevention of Chronic Obstructive Lung Disease 2017 Report： GOLD Executive Summary[J]. Am J Respir Crit Care Med， 2017， 195(5)：557-582.
[6]吴保民，孙波. 羧甲司坦治疗老年慢性阻塞性肺疾病急性加重期的疗效及对血清IL-8、TNF-α和IgE水平的影响[J]. 现代药物与临床， 2021， 36(3)：571-576.
[7]汪娟，靳攀. 沙丁胺醇气雾剂联合羧甲司坦片治疗AECOPD患者的临床效果[J]. 湖南师范大学学报（医学版）， 2022， 19(3)：13-16.
[8]郝文东，王国芳，张彩莲. 百令胶囊联合布地奈德福莫特罗粉吸入剂治疗稳定期慢性阻塞性肺疾病的疗效及机制[J]. 临床肺科杂志， 2016， 21(9)：1603-1606.
[9]中华中医药学会内科分会肺系病专业委员会. 慢性阻塞性肺疾病中医诊疗指南(2011版) [J]. 中医杂志， 2012， 53(1)：80-84.
[10]蔺敏，党苗苗，辛芳妮，等. 百令胶囊对中晚期非小细胞肺癌化疗患者免疫功能、生活质量及远期生存的影响[J]. 癌症进展， 2023， 21(3)：324-326.
[11]中华医学会呼吸病学分会慢性阻塞性肺疾病学组，中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南（2021年修订版）[J]. 中华结核和呼吸杂志， 2021， 44(3)：170-205.
[12]世界中医药学会联合会. 国际中医临床实践指南：慢性阻塞性肺疾病[J]. 世界中医药， 2020， 15(7)：1084-1092.
[13]国家中医药管理局. 中医病证诊断疗效标准[M]. 南京：南京大学出版社， 2012：20-21.
[14]Ko FW， Chan KP， Hui DS， et al. Acute exacerbation of COPD[J]. Respirology， 2016， 21(7)：1152-1165.
[15]Esposito A， Valentino MR， Bruzzese D， et al. Effect of carbocisteine in prevention of exacerbation of chronic obstructive pulmonary disease (CAPRI study)： An observational study[J]. Pulm Pharmacol Ther， 2016， 37：85-88.
[16]许光兰，李国生，赵媚，等. 慢性阻塞性肺疾病急性加重期中医治疗研究进展[J]. 吉林中医药， 2018， 38(4)：486-489.
[17]王胜，叶海勇，陈悦，等. 302例慢性阻塞性肺疾病急性加重期中医证候分型[J]. 北京中医药大学学报， 2015， 38(1)：57-62.
[18]程怡，范良，林月华，等. 老年患者稳定期COPD的中医辨证及康复措施治疗的临床观察[J]. 中国实验方剂学杂志， 2019， 25(24)：48-53.
[19]王丽峰，张春芳，田霞，等. 百令胶囊对频繁发作COPD病人免疫功能和肺功能的影响[J]. 内蒙古医科大学学报， 2019， 41(4)：388-390， 393.
[20]Xu H， Li S. Pharmacological effects of Bailing capsule and its application in lung disease research[J]. China Journal of Chinese Materia Medica， 2010， 35(20)：2777-2781.
[21]Zhang L， Zhao Y， Jia J， et al. Evaluation of the curative effects of Bailing capsules for treating chronic obstructive pulmonary disease： A protocol for systematic review and meta-analysis[J]. Medicine (Baltimore)， 2021， 100(25)：e25672.
[22]李小红，沈晓飞，闫雪. 慢性阻塞性肺疾病急性加重期的中医证型结合嗜酸性粒细胞分层的临床意义[J]. 浙江中医药大学学报， 2021， 45(9)：1013-1017， 1021.
[23]黄娟，刘家昌，方明，等. 慢性阻塞性肺疾病急性加重期患者EOS， PCT水平变化及临床意义[J]. 中国老年学杂志， 2022， 42(22)：5490-5492.
[24]陈伊莉，殷贝，李佑生. 人工冬虫夏草制剂的作用机制研究[J]. 河南中医， 2018， 38(2)：313-316.
[25]裴素娟. 西替利嗪联合百令胶囊治疗COPD患者疗效及对外周血嗜酸性粒细胞，气道功能以及血气指标的影响[J]. 实验与检验医学， 2022， 40(1)：59-61， 111.
[26]Zhao X， Wu Y. Correlations of silent information regulator of transcription 1 (SIRT1) expression， inflammatory factors， and oxidative stress with pulmonary function in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) [J]. Med Sci Monit， 2021， 27：e929046.
[27]Olatunji OJ， Tang J， Tola A， et al. The genus Cordyceps： An extensive review of its traditional uses， phytochemistry and pharmacology[J]. Fitoterapia， 2018， 129：293-316.
[28]魏闪闪，王婷，彭伟彪，等. 冬虫夏草提取液对60Coγ射线辐照小鼠睾丸组织氧化损伤的保护作用[J]. 海军医学杂志， 2022， 43(4)：364-369.
[29]Xue W， Ma J， Li Y， et al. Role of CD4+ T and CD8+ T lymphocytes-mediated cellular immunity in pathogenesis of chronic obstructive pulmonary disease[J]. J Immunol Res， 2022， 2022：1429213.
[30]Das G， Shin HS， Leyva-Gómez G， et al. Cordyceps spp.： A review on its immune-stimulatory and other biological potentials[J]. Front Pharmacol， 2021， 11：602364.

快速检索引用检索图表检索高级检索